Clinical Trials Browser

INDUSTRY × enasidenib × 90 days × Clear all

NCT02632708 2026-05-22

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute